| Name | Title | Contact Details |
|---|---|---|
Michael Paradise |
Chief Financial Officer | Profile |
MISSION STATEMENT The mission of San Diego Opera is to deliver exceptional vocal performances and exciting, accessible programs to diverse audiences, focusing on community engagement and the transformative power of live performance. VISION STATEMENT The San Diego Opera will be recognized internationally as a leading example of adaptability, innovation and sustainability in the operatic arts, promoting diversified programming and unique performance venues with world-class and emerging talent. CORE VALUES STATEMENT - Through excellence in innovative programming and education, San Diego Opera provides a lasting cultural service to the community. - Our tradition of excellence in fully staged opera is augmented with new models of opera and venues. Our unique and deep commitment to the community propels us to explore ways of increasing affordability and accessibility. - Through fiscal responsibility and nimble adaptation to the changing marketplace, we protect the future of San Diego Opera. - Our educational and community involvement coupled with relevant programming will build the audience of the future.
We are a trailblazing brand dedicated to inspiring and empowering women in sports. Our high-performance gear and cutting-edge technology enhance abilities and boost confidence. We create a supportive community that celebrates achievements, fosters connections, and encourages collaboration. Authentic, persevering, and dedicated to excellence, we redefine what it means to be a force in womens sports
Hawkins is a formulator, manufacturer, blender, distributor, and sales agent for thousands of industrial chemicals and reagent grade laboratory chemicals sold to municipalities and businesses throughout the Central United States. Thousands of water treatment facilities, manufacturers, food and dairy producers, research labs and many other organizations depend on Hawkins for the chemical products they need. These products range from potassium carbonate to chlorine to FCC grade citrates and phosphates. Our Mission To exceed our customers expectations as a high-quality, service-oriented chemical supplier. We will adapt quickly to the changing chemical needs of customers with a keen focus on technical expertise, teamwork, safety, profitability, and responsible care of the environment and of our community.
Unified Door & Hardware Group is a prominent distributor and service provider of commercial doors, hardware, and building specialties, located in Pennsauken, New Jersey. Established in 2013 from the merger of Commercial Hardware and TruFit, the company operates 31 locations nationwide and employs around 1,000 people, generating $92 million in revenue. In September 2024, it was acquired by Foundation Building Materials. The company offers a wide range of products and services across various construction divisions. This includes commercial doors and hardware, building specialties like bathroom partitions and fire protection, and access control systems. Unified Door & Hardware Group also provides custom fabrication, project management, professional engineering services, and installation for both new construction and aftermarket projects. They cater to diverse sectors such as healthcare, hospitality, government, and retail, working closely with contractors, developers, and building owners. Their extensive industry experience and commitment to personalized service set them apart in the market.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.